Court Rules Enanta Patent Invalid in Pfizer Paxlovid Case; Appeal Planned
Court Rules Enanta Patent Invalid in Pfizer Paxlovid Case; Appeal Planned
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts ("the Court") has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta's patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 ("the '953 Patent") in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets).
致力於爲病毒學和免疫學適應症開發小分子藥物的臨牀階段生物技術公司埃南塔製藥公司（納斯達克股票代碼：ENTA）今天宣佈，美國馬薩諸塞州地方法院（「法院」）已對輝瑞公司就Enanta的專利侵權訴訟提起的即決判決動議作出裁決，該訴訟要求對侵犯美國專利號11,358,953進行賠償（“「953 專利」）用於製造、使用和銷售輝瑞的 COVID-19 抗病毒藥物 Paxlovid（尼馬瑞韋片劑；利托那韋）平板電腦）。
The Court issued a summary judgment decision granting Pfizer's motion that the '953 Patent is invalid. In its decision, the Court also denied Enanta's partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit.
法院發佈了簡易判決裁決，批准了輝瑞關於'953年專利無效的動議。法院在裁決中還駁回了Enanta要求對侵權行爲作出即決判決的部分動議，認爲該動議沒有實際意義，因爲該動議允許對無效作出即決判決。埃南塔計劃就該裁決向聯邦巡迴上訴法院提出上訴。
